AUTL Autolus Therapeutics plc
28.89
+1.76 (+6%)
Previous Close
27.13
Open
27.12
Price To Book
4.54
Market Cap
1159823198
Shares
40,146,182
Volume
19,318
Short Ratio
Av. Daily Volume
69,949
NewsSee all news
- Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
- Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
- Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
- Alexandria Fully Leases New Built-to-Suit Facility to Autolus
- Biotech to create 170 jobs, invest $28M in new Rockville HQ
SEC filingsSee all SEC filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19605531
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605222
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601785
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19598393
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19519723
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 1/2 data presented at ASH December 2018.
AUTO3
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
AUTO2
Relapsed or refractory multiple myeloma
Phase 1 updated data noted 12/14 (86%) achieved molecular CR; OS 84% and 63% at 6 and 12 months, respectively - February 19, 2019.
AUTO1
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Latest News
- Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
- Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
- Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
- Alexandria Fully Leases New Built-to-Suit Facility to Autolus
- Biotech to create 170 jobs, invest $28M in new Rockville HQ
- Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters
- MoCo economic development officials plan satellite office in Boston
- London biotech firm planning new U.S. HQ, research facility in Rockville
- Autolus Therapeutics to Join NASDAQ Biotechnology Index
- Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes
- Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH
- Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting
- Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
- Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F
- Autolus Therapeutics to Present New Data at the ASH Annual Meeting
- Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting
- Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference
- Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
- UK biotech raises bumper $2 billion, despite Brexit blues
- T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics
SEC Filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19605531
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605222
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601785
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19598393
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19519723
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181246334
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181215283
- 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] 181199005
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181088028
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181068382